Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Cakir, S.
Right arrow Articles by Yildiz, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cakir, S.
Right arrow Articles by Yildiz, L.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 33:563-569 (2003)
© 2003 Foundation for Promotion of Cancer Research

The Sequencing of Radiation Therapy and Chemotherapy after Mastectomy in Premenopausal Women with Breast Cancer

Saban Cakir1, Bilge Gursel1, Deniz Meydan1 and Levent Yildiz2,+

1 Department of Radiation Oncology and 2 Department of Pathology, Ondokuz Mayis University, Medical School, Samsun, Turkey

Objective: The purpose of this study was to evaluate the prognostic importance of the sequencing of radiation therapy and chemotherapy after mastectomy in high-risk premenopausal women with breast cancer in addition to other known prognostic factors in the literature.

Methods: In this retrospective study, 176 premenopausal women with breast cancer were evaluated. The median age at referral was 39 years (range, 28–59 years); 106 patients had stage II and 70 had stage III disease. All were subjected to mastectomy. The median number of lymph nodes removed was 19. The influence of age, histological grade, number of nodes removed, number of positive nodes, tumor size, estrogen receptor status, lymphovascular invasion and sequencing of radiotherapy and chemotherapy on 5-year locoregional disease-free survival, 5-year systemic disease-free survival, 5-year disease-free survival and 5-year cancer-specific survival were studied.

Results: The 5-year locoregional disease-free survival was 94% for the entire patient population. Because of the small number of locoregional recurrences, none of the evaluated factors was prognostically significant for locoregional recurrence. The 5-year systemic disease-free, disease-free and cancer-specific survival rates were 72, 70 and 77%, respectively. On multivariate analysis of host, tumor and treatment-related factors, the number of positive nodes [RR 1.9 (95% CI: 1.36–2.63), RR 2 (1.46–2.84 ) and RR 1.8 (1.3–2.71), respectively], histopathological grade [RR 1.8 (95% CI: 1.24–2.65), RR 1.9 (1.34–2.88), RR 2.5 (1.65–4.07), respectively], estrogen receptor status [RR 3.5 (95% CI: 1.5–8.6), RR 3.9 (1.64–9.41), RR 2.5 (1.05–6.24), respectively] and the sequencing of radiotherapy and chemotherapy [RR 1.6 (95% CI: 1.17–2.39), RR 1.7 (1.25–2.54), RR 1.6 (1.14–2.43), respectively] were all significant independent predictors of outcome.

Conclusions: Our results show that in addition to traditional prognostic factors, the sequencing of radiation therapy and chemotherapy also predict for increased risk of any type of recurrence or further tumor death.

+ For reprints and all correspondence: Bilge Gursel, Department of Radiation Oncology, Ondokuz Mayis University, Medical School, 55139 Kurupelit, Samsun, Turkey. E-mail: bgursel{at}omu.edu.tr


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.